截至13:33，恒生港股通创新药指数（HSSCID）跌1.29%，权重股中，晶泰控股涨8.2%，同源康医药-B 涨1.6%，康方生物涨1.4%，锦欣生殖涨0.3%，欧康维视生物-B涨0.3%，和黄医药跌0.4%，四环医药跌 0.7%，远大医药涨0.3%，康哲药业涨1.1%，石药集团跌0.5%。 今年前7个月，江苏获批上市的创新药达14个，已超去年全年的13个。全国共有49个创新药获批上市。 中金公司指出，看好创新药长期产业发展趋势。国内工程师红利、丰富临床资源和支持性政策多边加持 下，国产创新药已逐渐从跟随时代走向FIC/BIC创新。经历几年耕耘，国内品种商业化放量，并有望受 益于支付端政策改革，创新药企盈利能力提升；在研管线数据优异，大额BD持续达成。进入2.0时代的 创新药产业已经逐步完成质的提升。 相关产品： 易方达恒生港股通创新药联接A(024328) 易方达恒生港股通创新药联接C(024329) ...

Core Viewpoint - The Hong Kong stock market opened slightly lower on August 6, with innovative drugs continuing to be active, particularly the high-profile Hong Kong Stock Connect innovative drug ETF (520880), which rose by 1.37% in early trading, aiming for a third consecutive daily gain [1]. Group 1: Company Developments - On August 5, Crystal Tech Holdings announced a pipeline collaboration agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical sector by 2025 [2][3]. - Crystal Tech Holdings has received an initial payment of USD 51 million under the final agreement and is entitled to further payments of USD 49 million (to be paid within 180 days), as well as potential milestone payments of up to USD 5.89 billion based on regulatory and commercial achievements, along with royalties based on annual net sales [3]. Group 2: Industry Trends - The domestic innovative drug sector is entering a period of technological breakthroughs, with the National Medical Products Administration reporting that 43 innovative drugs were approved in the first half of the year, a year-on-year increase of 59%, nearing the total of 48 for the entire year of 2024 [3]. - According to China International Capital Corporation, the long-term development trend of the innovative drug industry is promising, supported by domestic engineer advantages, abundant clinical resources, and favorable policies [3]. - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies, with many stocks in the sector showing strength as they enter the 2.0 era [3]. Group 3: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain, primarily consisting of innovative drug research and development companies [4]. - As of July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date, significantly outperforming the Hang Seng Index (23.50%) and the Hang Seng Tech Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6][7].

Core Viewpoint - The Hong Kong stock market opened slightly lower on August 6, with innovative pharmaceuticals continuing to be active, particularly the high-profile Hong Kong Stock Connect innovative drug ETF (520880), which rose by 1.37% in early trading, aiming for a third consecutive daily gain [1]. Company Highlights - Crystal Tech Holdings (晶泰控股) announced a pipeline collaboration agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical sector by 2025 [2][3]. - Crystal Tech has received an initial payment of USD 51 million under the final agreement and is entitled to further payments of USD 49 million (to be paid within 180 days), as well as potential milestone payments of up to USD 5.89 billion based on regulatory and commercial achievements, along with royalties based on annual net sales [3]. Industry Trends - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of the year, a 59% year-on-year increase, nearing the total of 48 for the entire year of 2024 [3]. - According to China International Capital Corporation (中金公司), the long-term development trend of the innovative pharmaceutical industry is promising, supported by domestic engineering talent, abundant clinical resources, and favorable policies [3]. - The innovative drug sector is transitioning from a follower to a leader in innovation, with domestic products expected to significantly participate in the global market over the next decade [3]. Market Performance - The Hang Seng Stock Connect Innovative Drug ETF (520880) is the first ETF to passively track the Hang Seng Stock Connect Innovative Drug Select Index, focusing on the innovative drug industry chain with a high concentration of leading stocks [5]. - As of July 31, the Hang Seng Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date, outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6].

金融界8月5日消息，上证指数高开高走，中证港股通医疗商业与服务综合指数 (港股通医疗商业， 931966)报1701.32点。 数据统计显示，中证港股通医疗商业与服务综合指数近一个月上涨10.64%，近三个月上涨12.75%，年 至今上涨22.94%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行 相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应 调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆、停牌等情形的处理， 参照计算与维护细则处理。 本文源自：金融界 作者：行情君 从指数持仓来看，中证港股通医疗商业与服务综合指数十大权重分别为：京东健康（16.57%）、阿里 健康（14.32%）、国药控股（13.85%）、平安好医生（11.27%）、上海医药（6.64%）、医脉通 （6.0%）、锦欣生殖（5.1%）、海吉亚医疗 ...

大摩指出，公司将利润下降归因于平均医疗保险每次就诊费用减少，显示各地区受DRG/DIP2.0导致的 报销压力加剧。大摩认为这对其他依赖公共保险的医院营运商，如海吉亚医疗(06078)、锦欣生殖 (01951)和爱尔眼科（300015）(300015.SZ)构成负面影响。 摩根士丹利发布研报称，华润医疗(01515)发布今年上半年利润警告，普通股股东应占净利润预计同比 下降20%至25%。若剔除与"燕化IOT协议"相关的2.1亿元人民币补偿，基础业务利润将同比下降55%至 60%，低于市场共识和大摩的预估。大摩予华润医疗目标价3港元，评级"减持"。 ...

Group 1 - Morgan Stanley reports that China Resources Medical (01515) has issued a profit warning for the first half of the year, with net profit attributable to ordinary shareholders expected to decline by 20% to 25% year-on-year [1] - Excluding the 210 million RMB compensation related to the "Yanhua IOT Agreement," the underlying business profit is projected to decrease by 55% to 60%, falling below market consensus and Morgan Stanley's estimates [1] - The company attributes the profit decline to a reduction in average medical insurance reimbursement per visit, indicating increased reimbursement pressure across regions due to DRG/DIP 2.0 [1] Group 2 - Morgan Stanley sets a target price of 3 HKD for China Resources Medical and maintains a "Reduce" rating [1] - The report suggests that the profit decline could negatively impact other hospital operators reliant on public insurance, such as Haijia Medical (06078), Jinxin Fertility (01951), and Aier Eye Hospital (300015.SZ) [1]

Group 1: Top Net Buy/Sell Companies - The top net buy company is BYD Company Limited (1211.HK) with a net buy amount of 14.245 billion CNY, representing a significant increase of 122,586,413 shares[8] - The second highest net buy is the Tracker Fund of Hong Kong (2800.HK) with a net buy amount of 6.866 billion CNY, with 274,875,500 shares acquired[8] - The top net sell company is China Mobile Limited (0941.HK) with a net sell amount of -2.151 billion CNY, reflecting a decrease of 25,038,050 shares[9] Group 2: Industry Distribution of Net Buy/Sell - The financial sector shows strong activity with major net buys from China Construction Bank (0939.HK) and China Life Insurance (2628.HK), totaling 3.020 billion CNY and 2.416 billion CNY respectively[8] - The consumer discretionary sector is also prominent, with significant net buys from BYD and Li Auto (2015.HK), amounting to 14.245 billion CNY and 2.137 billion CNY respectively[8] - In contrast, the telecommunications sector, led by China Mobile, shows a notable net sell, indicating a potential shift in investor sentiment[9] Group 3: Active Stocks - Meituan-W (3690.HK) is the most active stock in the Shanghai-Hong Kong Stock Connect with a total trading volume of 4.049 billion CNY and a net buy of 1.196 billion CNY[19] - Alibaba Group (9988.HK) follows closely with a trading volume of 3.790 billion CNY and a net buy of 0.654 billion CNY[19] - Xiaomi Corporation (1810.HK) also shows strong activity with a trading volume of 3.694 billion CNY and a net buy of 0.368 billion CNY[19]

Core Viewpoint - Morgan Stanley's research report indicates that China Resources Medical has issued a profit warning for the first half of this year, with net profit attributable to ordinary shareholders expected to decline by 20% to 25% year-on-year [1] Financial Performance - Excluding a compensation of 210 million yuan related to the YanHua IOT agreement, the underlying business profit is projected to decline by 55% to 60% year-on-year, which is below market consensus and Morgan Stanley's estimates [1] - Morgan Stanley sets a target price of 3 HKD for China Resources Medical and maintains a "Reduce" rating [1] Industry Impact - The company attributes the profit decline to a reduction in average medical insurance reimbursement per visit, indicating increased reimbursement pressure across regions due to DRG/DIP 2.0 [1] - This situation is expected to negatively impact other hospital operators that rely on public insurance, such as Haijia Medical, Gushengtang, Jinxin Fertility, and Aier Eye Hospital [1]

本文源自：金融界 作者：行情君 8月4日，锦欣生殖(01951)盘中下跌4.19%，截至15:45，报3.2元/股，成交3.0亿元。 锦欣生殖医疗集团有限公司是中美领先的辅助生殖服务机构，拥有和经营多家医院和医疗中心，主要提 供辅助生殖服务及相关治疗。根据弗若斯特沙利文报告，2018年，公司在中国辅助生殖服务市场中排名 第三，进行了20,958个体外受精取卵周期，市场份额约为3.1%，在非国有辅助生殖服务机构中排名第 一。 截至2024年年报，锦欣生殖营业总收入28.12亿元、净利润2.83亿元。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本 ...